These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 1708773

  • 1. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase.
    Larsen GR, Timony GA, Horgan PG, Barone KM, Henson KS, Angus LB, Stoudemire JB.
    J Biol Chem; 1991 May 05; 266(13):8156-61. PubMed ID: 1708773
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.
    Collen D, Stassen JM, Larsen G.
    Blood; 1988 Jan 05; 71(1):216-9. PubMed ID: 3120823
    [Abstract] [Full Text] [Related]

  • 3. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM.
    Circulation; 1991 Sep 05; 84(3):1216-34. PubMed ID: 1909220
    [Abstract] [Full Text] [Related]

  • 4. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
    Langer-Safer PR, Ahern TJ, Angus LB, Barone KM, Brenner MJ, Horgan PG, Morris GE, Stoudemire JB, Timony GA, Larsen GR.
    J Biol Chem; 1991 Feb 25; 266(6):3715-23. PubMed ID: 1847387
    [Abstract] [Full Text] [Related]

  • 5. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 6. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator.
    Hansen L, Blue Y, Barone K, Collen D, Larsen GR.
    J Biol Chem; 1988 Oct 25; 263(30):15713-9. PubMed ID: 3139674
    [Abstract] [Full Text] [Related]

  • 7. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR, Wu Z, Pauwels P, Lijnen HR, Collen D.
    J Am Coll Cardiol; 1992 May 25; 19(6):1350-9. PubMed ID: 1342779
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat.
    Larsen GR, Metzger M, Henson K, Blue Y, Horgan P.
    Blood; 1989 May 15; 73(7):1842-50. PubMed ID: 2496774
    [Abstract] [Full Text] [Related]

  • 9. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
    Lu HR, Lijnen HR, Stassen JM, Collen D.
    Blood; 1991 Jul 01; 78(1):125-31. PubMed ID: 1906351
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of clot-bound alpha 2-antiplasmin enhances in vivo thrombolysis.
    Reed GL, Matsueda GR, Haber E.
    Circulation; 1990 Jul 01; 82(1):164-8. PubMed ID: 1694738
    [Abstract] [Full Text] [Related]

  • 11. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits.
    Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang SP, Tung JS, Mark GE.
    Circulation; 1991 Jul 01; 84(1):244-53. PubMed ID: 1905593
    [Abstract] [Full Text] [Related]

  • 12. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
    Holvoet P, Dewerchin M, Stassen JM, Lijnen HR, Tollenaere T, Gaffney PJ, Collen D.
    Circulation; 1993 Mar 01; 87(3):1007-16. PubMed ID: 8443877
    [Abstract] [Full Text] [Related]

  • 13. Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits.
    Agnelli G, Pascucci C, Colucci M, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1992 Sep 07; 68(3):331-5. PubMed ID: 1440500
    [Abstract] [Full Text] [Related]

  • 14. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis.
    Mellott MJ, Stabilito II, Holahan MA, Cuca GC, Wang S, Li P, Barrett JS, Lynch JJ, Gardell SJ.
    Arterioscler Thromb; 1992 Feb 07; 12(2):212-21. PubMed ID: 1371932
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.
    Cambier P, van de Werf F, Larsen GR, Collen D.
    J Cardiovasc Pharmacol; 1988 Apr 07; 11(4):468-72. PubMed ID: 2453751
    [Abstract] [Full Text] [Related]

  • 16. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D, Stassen JM, Verstraete M.
    J Clin Invest; 1983 Feb 07; 71(2):368-76. PubMed ID: 6681615
    [Abstract] [Full Text] [Related]

  • 17. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
    Holvoet P, Laroche Y, Stassen JM, Lijnen HR, Van Hoef B, De Cock F, Van Houtven A, Gansemans Y, Matthyssens G, Collen D.
    Blood; 1993 Feb 01; 81(3):696-703. PubMed ID: 8427962
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers.
    Martin U, von Möllendorff E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G.
    Thromb Haemost; 1991 Nov 01; 66(5):569-74. PubMed ID: 1725068
    [Abstract] [Full Text] [Related]

  • 20. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model.
    Martin U, Fischer S, Kohnert U, Rudolph R, Sponer G, Stern A, Strein K.
    J Cardiovasc Pharmacol; 1991 Jul 01; 18(1):111-9. PubMed ID: 1719279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.